On September 4, the Drug Administration of Vietnam (Ministry of Health) issued a decision to administratively sanction Thanh Phat Pharmaceutical Joint Stock Company for many violations in the field of drug production and circulation.
According to the decision, Thanh Phat Company (headquartered in Phu Nghia Industrial Park, Hanoi) committed two main violations:
Failure to register for changes or supplements to the circulation registration certificate before circulating drugs, related to the Vinaplant liver Detoxification product.
Only maintain compliance with the principles and standards for good drug manufacturing practice (GMP) at level 4, not meeting the requirements according to regulations.
Pursuant to Decree 117/2020/ND-CP and Decree 124/2021/ND-CP, the Drug Administration has issued a decision: Fine a total of 180 million VND (80 million for violations of drug circulation registration; 100 million for the act of maintaining GMP at low levels).
Suspend production activities for 4.5 months for the company's line of medicinal herbs, traditional medicines and traditional medicine flavors in Phu Nghia Industrial Park, Hanoi. The suspension period is calculated from May 20, 2025 - the time the Department issued the official dispatch to temporarily suspend operations.
The management agency has not applied measures to revoke the certificate of eligibility for pharmaceutical business because the company has reported to correct some shortcomings.
Thanh Phat Company must pay the fine to the state budget within 10 days from the date of receipt of the decision. In case of non-voluntary compliance, it will be enforced according to the provisions of law.
In addition, the company has the right to appeal or initiate an administrative lawsuit against the penalty decision if it finds it unsuitable.
